Objectives:
To assess impact of left ventricular (LV) chamber remodeling on MitraClip (MClp) response.
Background:
MitraClip (MClp) is the sole percutaneous therapy approved for mitral regurgitation (MR) but response varies. LV dilation affects mitral coaptation; determinants of MClp response are uncertain.
Methods:
LV and mitral geometry were quantified on pre- and post-procedure two-dimensional (2D) transthoracic echocardiography (TTE) and intra-procedural three-dimensional (3D) transesophageal echocardiography (TEE). Optimal MClp response was defined as ≤mild MR at early (1-6 month) follow-up.
Results:
67 degenerative MR patients underwent MClp: Whereas MR decreased ≥1 grade in 94%, 39% of patients had optimal response (≤mild MR). Responders had smaller pre-procedural LV end-diastolic volume (94±24 vs. 109±25 ml/m2, p=0.02), paralleling smaller annular diameter (3.1±0.4 vs. 3.5±0.5 cm, p=0.002), and inter-papillary distance (2.2±0.7 vs. 2.5±0.6 cm, p=0.04). 3D TEE-derived annular area correlated with 2D TTE (r=0.59, p<0.001) and was smaller among optimal responders (12.8±2.1 cm2 vs. 16.8±4.4 cm2, p=0.001). Both 2D and 3D mitral annular size yielded good diagnostic performance for optimal MClp response (AUC 0.73-0.84, p<0.01). In multivariate analysis, sub-optimal MClp response was associated with LV end-diastolic diameter (OR 3.10 per-cm [1.26 – 7.62], p=0.01) independent of LA size (1.10 per-cm2 [1.02 - 1.19], p=0.01); substitution of mitral annular diameter for LV size yielded an independent association with MClp response (4.06 per-cm2 [1.03 - 15.96], p=0.045).
Conclusions:
Among degenerative MR patients undergoing MClp, LV and mitral annular dilation augment risk for residual or recurrent MR, supporting the concept that MClp therapeutic response is linked to sub-valvular remodeling.